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Background: Randomised controlled trials (RCT) are highly influential upon medical decisions. Thus RCTs must not
distort the truth. One threat to internal trial validity is the correct prediction of future allocations (selection bias).
The Berger-Exner test detects such bias but has not been widely utilized in practice. One reason for this non-utilisation
may be a lack of information regarding its test accuracy. The objective of this study is to assess the accuracy of the
Berger-Exner test on the basis of relevant simulations for RCTs with dichotomous outcomes.
Methods: Simulated RCTs with various parameter settings were generated, using R software, and subjected
to bias-free and selection bias scenarios. The effect size inflation due to bias was quantified. The test was applied in
both scenarios and the pooled sensitivity and specificity, with 95% confidence intervals for alpha levels of 1%,
5%, and 20%, were computed. Summary ROC curves were generated and the relationships of parameters with test
accuracy were explored.
Results: An effect size inflation of 71% - 99% was established. Test sensitivity was 1.00 (95% CI: 0.99 – 1.00) for
alpha level 1%, 5%, and 20%; test specificity was 0.94 (95% CI: 0.93 – 0.96); 0.82 (95% CI: 0.80 – 0.84), and 0.56
(95% CI: 0.54 – 0.58) for alpha 1%, 5%, and 20%, respectively. Test accuracy was best with the maximal procedure
used with a maximum tolerated imbalance (MTI) = 2 as the randomisation method at alpha 1%.
Conclusions: The results of this simulation study suggest that the Berger-Exner test is generally accurate for
identifying third-order selection bias.
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Bias has been defined as systematic error or deviation
from the truth in results or inferences [1]. Selection bias
is one form of systematic error that interferes with the
internal validity of clinical trials [2] and may lead to
favouring one treatment group over another [3]. This
bias is based on knowledge about patient characteristics
that are known to be conducive to successful trial out-
comes together with foreknowledge regarding the alloca-
tion of such patients in a specific sequence of interventions* Correspondence: neem@global.co.za
1SYSTEM Initiative/Department of Community Dentistry, Faculty of Health
Sciences, University of the Witwatersrand, 7 York Rd., Parktown,
Johannesburg 2193, South Africa
Full list of author information is available at the end of the article
© 2014 Mickenautsch et al.; licensee BioMed C
Creative Commons Attribution License (http:/
distribution, and reproduction in any medium
Domain Dedication waiver (http://creativecom
article, unless otherwise stated.(i.e., test and control interventions). Accordingly, such
patients may consequently be scheduled to receive the
particular intervention, thus creating a more favourable
outcome than that of any other type of intervention
(i.e., the control intervention). Theoretically, generation
of a random allocation sequence in randomised control
trials (RCT) balances all known and unknown patient
characteristics (and risk factors) between groups and
may thus ensure an equal chance for any patient, with
any characteristic, to receive either type of intervention.
However, such random allocation may be subverted: ei-
ther when trial subjects are selected before generation
of the random allocation sequence; the random alloca-
tion sequence is directly observed, or when the random
allocation sequence is correctly predicted before subjectentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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as the introduction of first-, second- and third-order se-
lection bias, respectively [2].
“Third-order residual” selection bias is present when,
despite the application of what may generally be consid-
ered to be an adequate allocation concealment process,
the result of this process was unsuccessful and subver-
sion has occurred; i.e., through correct prediction of the
random sequence allocation [2]. In such a situation
opaque envelopes and/or central randomisation may be
used to prevent direct observation of the random se-
quence, but future allocations can still be predicted, even
if not observed directly. This may most easily be under-
stood in terms of an unmasked trial that uses permuted
blocks of size two, because here, even if the allocation
sequence is never directly observed, it is still easy to de-
termine every second allocation, since it must differ
from the one just before it.
In this context, correct prediction of the random alloca-
tion sequence is a prerequisite for selection bias. Without
prediction of future allocations, no third-order residual se-
lection bias is possible but although a situation in which
future allocations are predicted can be imagined, these
predictions are not acted upon. The focus of this study is
the situation in which this prediction is acted upon. In this
case, the investigators may select healthier patients, or
those patients more likely to respond well, when their
treatment is due up, and sicker patients when the control
is due up. The fact that those parties with the greatest
vested interest in the outcome of the trial are the very
ones conducting the trial makes it clear that there is an in-
centive to use whatever discretion may be available to en-
sure that the desired outcome is obtained.
It should not be surprising therefore, that overesti-
mation of a treatment effect through bias has been ob-
served to be more common than underestimation [4].
Moreover, Berger (2005) documents no fewer than 30
actual trials exhibiting characteristics of this type of se-
lection bias [2]. Selected empirical evidence regarding
the effect of selection bias shows an overestimation of
treatment effects caused by lack of adequate random se-
quence generation and allocation, as well as by a lack of
adequate allocation concealment, of 30% [5] to 51% [6],
and of 13.3% [7] to 54% [8], respectively. Clearly, then,
selection bias is a major problem, and needs to be con-
trolled. Such control may take the form of prevention [9],
detection [10] or correction [11]. All three approaches are
important [2].
Prior to the development of the Berger-Exner test in
1999 [10], only basic methods were available for detect-
ing selection bias. These would include the baseline
comparisons that are standard in clinical trial reports.
The Berger-Exner test is the first analysis that aims to
directly detect selection bias by studying the mechanismthrough which it occurs (or does not occur, as the case
may be). However, the result of a simple literature search
in PubMed and GoogleScholar (30.09.2013), using “Berger-
Exner test” as search term, suggests that since its
development the test has been adopted as part of trial
methodology in only six RCTs [12-17] and one RCT
protocol [18], so far. These trials and the protocol were
published during an eight-year period from 2005 – 2013
and cover topics in the fields of psychology [12] and in-
ternal medicine [14,15,18] and investigations related to
drug addiction [13] and to HIV/AIDS [16,17]. The trials
were implemented by trialists, mostly based in the USA
[12-14,16,17], but also in South Africa, the UK and
Jamaica [14]; Italy, Switzerland and Turkey [15]; India
[16] and Australia [17]. The need for further in-depth
investigations notwithstanding, the results of a subse-
quent literature search in PubMed (01.10.2013), with
names of the trialists as search terms, appear to suggest
that these trialists did not use the Berger-Exner test in
previous or subsequent RCTs.
Reasons for the apparent low utilization of the Berger-
Exner test in RCTs may be ascribed to a lack of informa-
tion regarding its test accuracy. Against this background,
the aim of this study was to assess test accuracy on the
basis of relevant simulations for RCTs with dichotomous
outcomes.
Methods
In order to investigate the accuracy of the Berger-Exner
test for detecting third-order selection bias in RCTs, the
numbers of true positive (TP), true negative (TN), false
positive (FP), and false negative (FN) results were ob-
served from RCT simulations. A ‘true positive’ test result
(TP) was observed when the test indicated a positive re-
sult in the presence of bias and a ‘true negative’ test result
(TN) was observed when the test indicated a negative re-
sult in the absence of bias. Accordingly, a ‘false positive’
test results (FP) was observed when the test indicated a
positive result in the absence of bias and a ‘false negative’
test result (FN) was observed when the test indicated a
negative result in the presence of bias. These numbers
were converted into two rates: the test sensitivity and test
specificity. The test sensitivity is defined as the proportion
of cases with third-order selection bias in relation to the
total number of cases that show positive test results, and
the test specificity is defined as the proportion of cases
without third-order selection bias in relation to the total
number of cases that show negative test results [19]. For
high accuracy it is ideal that sensitivity and specificity have
somewhat reasonably high percentages, i.e., > 80%. In
order to obtain a summarized predictive value of the
two rates, the Diagnostic Odds Ratio (DOR) was com-
puted. The DOR combines sensitivity and specificity
into one single predictive summary measure and is
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may range from zero to infinity, has no pre-defined cut-
off threshold and is utilized for comparing the predict-
ive evidence strength of different diagnostic parameter
settings. A DOR value of, or close to 1.00 provides no
predictive evidence and corresponds with the rising di-
agonal in Summary Receiver Operating Characteristic
(SROC) graphs. The higher the DOR value (>1.00), the
better the predictive accuracy [20].
Seven different randomisation procedures for each of
three “trait frequencies” within each of the three sample
sizes (N) were included. The trait frequency (TF) was
defined as the percentage of subjects with a characteris-
tic/trait ‘X’. Such trait was assumed to function as a con-
founding factor that would cause intervention success
(Y = 1), regardless of the type of intervention group.
Trial simulation and parameters
For the purpose of this study an RCT simulation was ob-
tained by assuming the comparison of two interventions
(Intervention A and B) with dichotomous outcomes
(Intervention failure: Y = 0; Intervention success: Y = 1).
A simulated RCT consisted of three components: (i) a
sequence of subject ID (accession) numbers; (ii) a se-
quence of the Reverse Propensity Score (RPS) [11] per
subject ID with regard to the propensity of the subject
to be allocated to Group A; and (iii) a sequence of di-
chotomous outcomes per subject ID (Y = 1 or 0). The
RPS reflects the probability of allocation of a patient to
group A [2]. For example, with block size 4 and an
[ABAB] block, the sequence of RPS values would be 2/4,
1/3, ½, 0/1, respectively, reflecting the ratio of the num-
ber of remaining A allocations within the block to over-
all remaining allocations within the block.
The parameters Trait Frequency (TF), subject number
(N) and type of randomisation method (RM) were intro-
duced into the simulation (Table 1). The seven random-
isation methods were: fixed block randomisation with
block size 4, 6, or 8; block randomisation with randomly
varying block size 4, 6, 8 with equal probability (1/3) and
the maximal procedure [9] with a maximum tolerated
imbalance (MTI) of 2, 3, and 4. The Trait frequency
(TF) was set to be 10%, 20% or 50% of the total number
of subjects (N), which in turn was set to be 120, 240 or
480 subjects.
Study scenarios
As both interventions were assumed to have no effect,
thus would not lead to ‘success’ on its own, the distribu-
tion of subjects with trait ‘X’ (Y = 1) among groups A
and B served as an indicator for the presence/absence of
selection bias. When subject allocation strictly followed
a true random sequence, all subjects with trait ‘X’ were
evenly distributed between groups A and B and neitherintervention group was superior to the other (= Scenario
1: No selection bias). Subversion of the random alloca-
tion by correct prediction of the random sequence
through use of the RPS and knowledge about which of
the subjects carry trait ‘X’ allowed allocation of these
subjects in favour of intervention group A (= Scenario 2:
third-order selection bias). In this scenario, intervention
A was superior to intervention B solely by virtue of an
uneven distribution of subjects with trait ‘X’ (Y = 1), be-
ing equal to the specified TF.
Scenario 1 was simulated, using R statistical software,
by assigning the first (N*TF)/100% of participants to Y = 1,
and all others to Y = 0. Scenario 2 was simulated, using
R statistical software, by assigning Y = 1 in accordance
with the highest RPS, favouring intervention A above B
as per TF. For each parameter set, 25 individual random
sequences (‘runs’) were generated.
In order to illustrate the ‘effect size inflation due to
third-order selection bias’ at the various parameter set-
tings of TF and N in the RCT simulations, fixed effect
meta-analysis was conducted of all simulated RCTs per
TF/N setting, using RevMan 4.2.10 statistic software.
Pooled Odds ratios (OR) with 95% Confidence Intervals
(CI) were computed from dichotomous datasets consist-
ing per intervention group of (i) the number of subjects
with intervention failure, Y = 0 and (ii) the total number
of subjects per TF/N setting. A Ratio of Odds Ratios
(ROR) was calculated, being the Odds ratio (OR) of all
datasets of Scenario 2 divided by the OR of Scenario 1.
In absence of bias (Scenario 1) the OR is 1.00, indicating
no difference in intervention failures between test- and
control group. An OR below 1.00 indicates less interven-
tion failures in the test group and an OR above 1.00 in-
dicates less intervention failures in the control group. In
Scenario, 2 bias favours the test group over that of the
control group, i.e.: having less numbers of failed inter-
vention (n), thus resulting in a lower OR. Because the
OR of Scenario 1 is lager than the OR of Scenario 2, the
calculated ROR is necessarily lower than 1.00. In line
with convention [21], an ROR less than 1.0 indicates an
overestimation in the effect size of the former group of
datasets in comparison to the effect size of the referent
group of datasets. From the thus established ROR, an ef-
fect size overestimation in percent, [1 – ROR] × 100%,
was calculated. All OR were computed using RevMan
4.2.10 statistic software from the subject number (N)
and numbers of failed intervention (n) per intervention
group.
As the actual effect of both interventions was of no
interest within this context, it was set at zero (Y = 0).
Hence, when compared with each other, neither inter-
vention would yield any result superior to that of the
other (= Odds ratio 1.00). Such setting allowed investiga-
tion of the bias effect alone.
Table 1 Generated parameter sets for both scenarios















Maximal procedure/MTI = 2
120
10/12




















Maximal procedure/MTI = 3
120
10/12




















Maximal procedure/MTI = 4
120
10/12





















PSN = Parameter set number; RM = Randomisation method; TF = Trait frequency; N = Subject number; n = Number of subjects per TF; BS = Block size;
MTI = Maximum tolerated imbalance; Fixed = Fixed block randomisation.
Varying = Block randomisation with randomly varying block size 4, 6, 8 with equal probability (1/3).
Mickenautsch et al. BMC Medical Research Methodology 2014, 14:114 Page 4 of 11
http://www.biomedcentral.com/1471-2288/14/114From the various parameters (Randomisation method,
TF and N) a total of 63 different parameter sets for the
simulated RCTs were generated and are presented in
Table 1. All RCT simulations were conducted in four
steps, using R statistical software, based on the generated
variables: ID, BLOCK, TRT, RPS, Y
– Step 1: Generation of subject identification (ID) i = 1:N;
– Step 2: Generation of randomisation-blocks/MTI
(BLOCK) and randomisation according to different
RM);– Step 3: Generation of 2-arm treatment (TRT) in
each block. For fixed and varying block randomisation,
two treatments have equal probability to be assigned
to either group, and within each block, the number of
each treatment should be the same, Thus random
numbers were generated from a standard uniform
distribution for a simulated RCT with block size mi,
i = 1,…,N, m/2 of which those above the median were
assigned as intervention A (TRT = 1), and all other
m/2 were assigned as intervention B (TRT = 0).
For the maximal procedure (MP), the generation of
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the qualified random sequence should satisfy I(D) < =
MTI and IN(D) = 0, where Ik(D) = |Sk,A(D)-Sk,B(D)|,
and Sk,A(D) = sum(Xi(D)), I = 1,…,k, and Sk,B(D) =
k- Sk,A(D), where Xi(D) = 1, if sequence D assigns the
ith patient to treatment group A, Xi(D) = 0, if sequence
D assigns the ith patient to treatment group B.
– Step 4: Calculation of the RPS from the generated
block and treatment, using code “rps.gen” in R
(Additional file 1: Appendix file 1) on the basis of
the block information (BLOCK) and the treatment
information (TRT).
Bias testing
The Berger-Exner test has been applied for bias testing.
The test consisted of linear regression analysis, separately
per treatment group, including the RPS as independent,
and the Y-values as dependent variables [2]. Regression
analysis was conducted separately per intervention group
and the resulting p-values were recorded. In order to in-
vestigate the influence of various alpha levels on the test
accuracy, alpha was set at 1%, 5% and 20%.
A true negative (TN) result was established when both
p-values for intervention group A and B were above
0.01; 0.05 or 0.20 for alpha 1%, 5% and 20% (two-sided),
respectively. A true positive (TP) result was established
when at least one of the p-values of either intervention
group was below 0.01; 0.05 or 0.20 for alpha 1%, 5% and
20%, respectively. The number of false positive (FP) results
was calculated by subtracting the total number of TN
from the total number of runs per parameter set; i.e., FP =
25 – TN. The number of false negative (FN) results was
calculated by subtracting the total number of TP from the
total number of runs per parameter set; i.e., FN = 25 – TP.
Data analysis and summary measures
From the 63 separate parameter sets, the established
total numbers of true negative/false positive (TN/FP) and
true positive/false negative (TP/FN) results, per set alpha
level, were entered into Meta-DiSc Version 1.4 statistical
software [22] and the pooled specificity and sensitivity
with 95% Confidence Intervals (CI) for each alpha level
were computed. In addition, symmetrical Summary
Receiver Operating Characteristic (SROC) curves per
alpha level were generated from this data. The SROC
curve shows the relationship of the sensitivity and the
complement of the specificity for all the individual test
results; i.e., the fractional relationship between TP (TP/
(TP + FN)) and FP (FP/(FP + TN)).
The influence of parameters N, TF and RM was investi-
gated by computing the Diagnostic Odds Ratio (DOR with
95% CI) from the relevant TN/FP and TP/FN data per
parameter setting of each study parameter per alpha level
(Table 1), using Meta-DiSc Version 1.4 statistical software.All data pooling, using Meta-Disc 1.4 software, was
based on the standard Der Simonian Laird random-effects
model [22]. The DerSimonian Laird method produces a
random-effects meta-analysis that incorporates an assump-
tion that different studies are estimating different, yet re-
lated, effects. The model may not be optimal but remains
valid even when the random effects are not normally dis-
tributed. In addition, the model allows the treatment effects
to differ across runs, with an underlying true effect, and a
between-runs variance, by using a non-iterative model to
estimate the treatment effect variance.
Results
For the purpose of this study the true effect size of the
simulated RCT results was set at OR 1.00. Third order
selection bias effected an inflation of the true effect size
to a range between ROR 0.01 – 0.29, thus reflecting an
overestimation ranging from 71% - 99%. Table 2 pre-
sents the Odds ratios (OR) that were computed from the
pooled number of subjects with failed intervention (n)
and the total subject numbers (N), as well as the calcu-
lated ROR and percent overestimation (OE%) per par-
ameter setting for Scenario 1 and 2.
A total of 3150 runs were conducted, 1575 for each
scenario. From these, testing in scenario 1 yielded 1488;
1294 and 883 true negative (TN) results for alphas 1%; 5%
and 20%, respectively. Testing in scenario 2 yielded 1574;
1574 and 1575 true positive (TP) results for alphas 1%; 5%
and 20%, respectively (Additional file 2: Appendix file 2).
Test sensitivity and specificity
Computation of the pooled test sensitivity and specificity
was based on the TP/FN and TN/FP data from the 63 sep-
arate parameter sets (Table 1, Additional file 2: Appendix
file 2), per alpha level. The pooled sensitivity was 1.00
(95% CI: 0.99 – 1.00) for alpha level 1%, 5% and 20%. The
pooled test specificity was 0.94 (95% CI: 0.93 – 0.96) for
alpha level 1% and 0.82 (95% CI: 0.80 – 0.84) and 0.56
(95% CI: 0.54 – 0.58) for alpha 5% and 20%, respectively.
The generated SROC curves (Figures 1, 2, 3) indicated
highest overall test accuracy when alpha was set at 1%.
Association of trial parameters with test accuracy
Diagnostic Odds Ratios (DOR) were computed per alpha
level based on the TP/FN and TN/FP data from 21 rele-
vant parameter sets of parameter settings for the number
of subjects (N) and trait frequency (TF), as well as from 9
relevant parameter sets of settings for randomisation
method (RM) (Table 1, Additional file 2: Appendix file 2).
The results are presented in Table 3.
Higher accuracy was observed for all parameters when
alpha was set at 1%. In comparison to all other random-
isation methods, the results further suggest highest test
accuracy with maximal procedure [9] with MTI = 2 as
Table 2 Inflation of effect size due to 3rd order selection bias
Parameter setting
Scenario 1* Scenario 2**
ROR/OE%Group A Group B
OR 95% CI
Group A Group B
OR 95% CI
n N n N n N n N
TF = 10% - N = 120 19950 21000 19950 21000 1.00 0.92 – 1.09 18912 21000 20988 21000 0.04 0.03 – 0.05 0.04/96%
TF = 10% - N = 240 31500 42000 31500 42000 1.00 0.94 – 1.06 37824 42000 41976 42000 0.02 0.02 – 0.03 0.02/98%
TF = 10% - N = 480 63000 84000 63000 84000 1.00 0.96 – 1.04 75624 84000 83976 84000 0.01 0.01 – 0.01 0.01/99%
TF = 20% - N = 120 18900 21000 18900 21000 1.00 0.94 – 1.07 17117 21000 20681 21000 0.09 0.08 – 0.10 0.09/91%
TF = 20% - N = 240 37800 42000 37800 42000 1.00 0.96 – 1.07 34242 42000 41343 42000 0.08 0.07 – 0.09 0.08/92%
TF = 20% - N = 480 75600 84000 75600 84000 1.00 0.97 – 1.03 68493 84000 82717 84000 0.08 0.07 – 0.08 0.08/92%
TF = 50% - N = 120 15750 21000 15750 21000 1.00 0.96 – 1.05 13417 21000 18093 21000 0.29 0.27 – 0.30 0.29/71%
TF = 50% - N = 240 39900 42000 39900 42000 1.00 0.97 – 1.03 26858 42000 36150 42000 0.29 0.28 – 0.30 0.29/71%
TF = 50% - N = 480 79800 84000 79800 84000 1.00 0.98 – 1.02 53812 84000 72178 84000 0.29 0.28 – 0.30 0.29/71%
TF = Trait frequency; N = Subject number; OR = Pooled Odds ratio; CI = Confidence interval; n = Pooled number of subjects with failed intervention (Y = 0);
N = Pooled total umber of subjects;
ROR = Ratio of Odds ratios; OE% = Percent overestimation/inflation of true effect size.
*No bias; **3rd order selection bias.
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at alpha 1%. For all alpha levels, test accuracy appeared
to be associated with lower block size (BS) when fixed
randomisation was used, but not with subject number
(N) or trait frequency (TF).Figure 1 Summary Receiver Operating Characteristic (SROC) curve co
SE = Standard error.Discussion
The aim of this study was to assess the accuracy of the
Berger-Exner test in identifying ‘third-order residual se-
lection bias’ on the basis of relevant simulations for
RCTs with dichotomous outcomes. As the accuracy wasncerning test accuracy at alpha level 1%. AUC = Area under curve;
Figure 2 Summary Receiver Operating Characteristic (SROC) curve concerning test accuracy at alpha level 5%. AUC = Area under curve;
SE = Standard error.
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this study may have been limited by several methodo-
logical factors.
Limitations of the current study method
In this simulation study only one single confounding
factor, ‘trait X’, was utilized. This can be regarded as an
oversimplification because many unknown confounding
factors that can influence trial outcomes may indeed
exist. These factors may interact in an enhancing or sup-
pressive manner and their compound influence on the
study results may lead to over- or underestimation of
any intervention types studied. Alternatively, such fac-
tors may also have no impact at all. The ‘trait frequency’
that was simulated for the study samples may also not
always be specific, but may have varying value.
The assumption of equivalence between both interven-
tions was set as an absolute (= Odds ratio 1.00). However,
even if interventions with almost the same treatment ef-
fects were compared, such effects would seldom be of
absolute equivalence, even if no statistically significant
differences were observed. Furthermore, the relation-
ship of sample size to observed effect estimates in realworld randomised control trials may affect test accur-
acy. For these reasons the perfect settings of the chosen
simulation method may have contributed to artificially
increased test accuracy.
Notwithstanding such limitations, the chosen trial
simulation could establish the rationale of test accuracy
of the Berger-Exner test by providing first insights as to
which aspects, present in randomised control trials, may
affect its utility.
Discussion of results
As RCTs are highly influential in medical decisions, they
must not distort the truth. One threat to internal trial
validity is the correct prediction of future allocations
(third-order selection bias). Against the background of
high systematic error, due to third-order residual selection
bias and quantified as effect-size overestimation ranging
from 71 – 99% (Table 2), the results of this trial simulation
show high sensitivity and specificity of the Berger-Exner
test (Table 3) for RCTs with dichotomous outcomes.
These results were affected by the chosen alpha level
and block/MTI size, but not by trait-frequency level and
sample size: While the test sensitivity values were the
Figure 3 Summary Receiver Operating Characteristic (SROC) curve concerning test accuracy at alpha level 20%. AUC = Area under curve;
SE = Standard error.





Alpha 1% Alpha 5% Alpha 20%
DOR* 95% CI* DOR* 95% CI* DOR* 95% CI*
N
120 835 396 - 1763 212 110 - 406 62 33 - 117
240 698 334 - 1455 242 124 - 474 71 37 - 135
480 668 325 - 1374 234 122 - 451 65 34 - 122
TF
10% 948 443 - 2027 238 124 - 458 64 34 - 120
20% 785 378 - 1626 251 130 - 484 69 37 - 131
50% 547 272 - 1101 204 107 - 391 64 34 - 120
RM
Fixed/BS = 4 995 311 - 3186 500 176 - 1420 113 43 - 299
Fixed/BS = 6 666 225 - 1976 233 86 - 630 86 32 - 227
Fixed/BS = 8 566 196 - 1638 185 69 - 498 63 24 - 166
Varying 723 242 - 2166 182 69 - 494 52 20 - 136
MP/MTI = 2 1456 432 - 4906 395 108 - 805 72 27 - 189
MP/MTI = 3 712 239 - 2126 224 83 - 604 53 20 - 140
MP/MTI = 4 474 160 - 1404 144 54 - 382 43 16 – 114
CI = Confidence Intervals; Fixed = Fixed block randomisation; BS = Block size; MTI = Maximum tolerated imbalance; Fixed = Fixed block randomisation;
Varying = Block randomisation with randomly varying block size 4, 6, 8 with equal probability (1/3); MP =Maximal procedure; MTI = Maximum tolerated imbalance;
N = Subject number; TF = Trait frequency;
RM = Randomisation method.
*Decimals rounded.
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with increasing alpha level. DOR values increased with
lower alpha and lower block size/MTI.
How these results relate to the available evidence pro-
vided by real-world RCTs that have utilized the Berger-
Exner test in the past remains unclear, as most of these
investigated continuous outcomes: Depression scale and
Mental health summary scores [12]; Addiction with-
drawal severity scores [13]; percentage of days of disease
[14]; mean absolute change in artery dilation [17]. For
this reason it is difficult to apply the results of this simu-
lation study to the reported settings and test results of
these RCTs. The two RCTs that did include dichotom-
ous outcomes in terms of disease and morbidity rates re-
ported a negative Berger-Exner test at alpha level 5%
and employed varying block randomisation [15] and
fixed block randomisation with block size 8 [16]. The re-
sults of this simulation study suggest comparatively low
test accuracy at these parameter settings with DOR 182
(95% CI: 69 – 494) and DOR 185 (95% 69 – 498), re-
spectively (Table 3). Through the presented trial simula-
tion, a mean percentage (SD = Standard deviation) of
79% (SD = 8%) true negative (TN) test results of all test
results (see Additional file 2: Appendix file 2/PSN 19–27
and 28–36, respectively) was achieved for fixed block
randomisation with block size 8 and varying block ran-
domisation, each, at alpha 5%. However, the likelihood
of such still reasonably high test accuracy for correctly
identifying absence of third-order selection bias, may be
lower in both RCTs [15,16] (and thus, the reported ab-
sence of selection bias in these trials less reliable) as the
test accuracy identified in this simulation study may be
artificially increased, owing to the stated limitations of
the chosen study method. However, due to the current
lack of randomised control trials that have used the
Berger-Exner test, more in-depth considerations as to
the meaning of the reported test results cannot yet be
made.
Notwithstanding the current limitations, a routine ap-
plication of the Berger-Exner test in RCTs may have the
advantage of providing a quantitative answer to the
question as to whether the random allocation sequence
concealment was effective or not. The ‘Risk of bias’ as-
sessment tool, currently advocated by the Cochrane Col-
laboration does not provide such answer [23]. RCT
reports cannot provide proof of absence of third-order
selection bias during the trial simply by virtue of stating
in detail the use of adequate concealment methods. Al-
though, RCTs that reported adequate concealment were
found to yield lower effect estimates than those with in-
adequate or unknown allocation concealment, such ob-
servations were limited as it was not possible to predict
direction and magnitude of such effect-size changes [24].
Such uncertainty may partially be due to the possibilitythat some RCTs, which reported adequate concealment
were compromised by correct prediction, without unmask-
ing of the random allocation sequence during the trials.
An inclusion of the Berger-Exner test into routine
RCT methodology, together with the reporting of under-
lying test data (dichotomous intervention outcome and
RPS score per trial subject) and test result may thus aid
in the correct distinction between RCTs with adequate
or inadequate concealment. Such information may bene-
fit possible statistical RPS-based bias correction [11,25]
and RCT evidence rating: Evidence rating systems, such
as the GRADE system, have been developed for rating
evidence quality and strength of recommendations de-
rived from such evidence. The GRADE system in par-
ticular recommends quality downgrading of evidence
from RCTs that lack adequate allocation concealment.
However, it has been observed that empirical evidence
in support of GRADE criteria is limited and that the
GRADE system has been shown to give inconsistent re-
sults [26]. Additionally, the investigation of a quantita-
tive approach to bias-risk assessment appears not to be
the current focus of the Cochrane Bias Methods Group
(BMG), so far [27]. For that reason, the Berger-Exner
test may prove to be a useful tool in providing an empir-
ical basis for RCT evidence rating.
Recommendation for further research
Wide adoption of the Berger-Exner test into general
RCT methodology of future studies could aid the verifi-
cation of the current simulation results in practice. In
addition, several aspects that require further investiga-
tion have emerged during the process of this study:
Even though the study simulation relied on binary
values (Y = 0 / Y = 1) as the dependent variable, difficul-
ties in using logistic instead of linear regression were ob-
served. For scenario 2 (third-order selection bias), the
situation may arise that for all subjects in one treatment
group there may be only one value of outcome (Y = 0 or
Y = 1). In such cases, logistical regression fails when Y is
treated as the dependent variable. In contrast, linear re-
gression treats the RPS value as the independent vari-
able, which is why it was selected as the analytical
method for use in this trial simulation.
Other aspects of this study also require further investi-
gation. Some relate to the test accuracy in RCTs with
continuous outcomes, as well as answers to questions as
to why the observed test accuracy in trial simulations
with dichotomous outcomes was higher with the max-
imal procedure than with other randomisation methods
at alpha 1% and why the test accuracy was reduced at
alpha 5% and 20%. Other questions still begging answers
are related to reasons why test accuracy is reduced with
higher block size/MTI, and to what the cause for false
positive/false negative test results would be. Furthermore,
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tion at more real-world RCT simulation settings, such as
varying effect estimates between competing interventions.
Such future studies will show whether the ideal assump-
tions (i.e., absolute effect equivalence between interven-
tions) on which the presented simulation method was
based would, or would not have resulted in artificially in-
creased test accuracy.
Conclusion
The results of this simulation-based investigation sug-
gest that the Berger-Exner test may successfully detect
third-order selection bias at high accuracy under the
condition that the maximal procedure with MTI = 2 as
randomisation method is used with alpha set at 1%.
However, some questions remain as to the empirical ac-
curacy of this test and further research in this field is
needed. Notwithstanding the limitations of this study, a
routine adoption of the test into general RCT method-
ology is recommended as this may assist in the real-life
corroboration of the simulation results and further in-
vestigation of test characteristics.
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